Business Wire21h
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
FDA accepts Arrowhead's NDA for plozasiran
Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...
FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment
Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...
Arrowhead says FDA accepts NDA for investigational plozasiran
Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...
Healio1d
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’
In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
BioSpace4d
JPM25 Day One: Pfizer, BioNTech, Moderna and More Present Pipeline Updates
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...
Piper Sandler Reaffirms Their Buy Rating on X4 Pharmaceuticals (XFOR)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of ...